In addition, as indole treatment stimulates the expression of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), a master regulatory gene of glycolysis, and suppresses macrophage proinflammatory activation in a PFKFB3-dependent manner, and, moreover, myeloid cell-specific PFKFB3 disruption exacerbates the severity of HFD-induced hepatic steatosis and inflammation, researchers speculate that the protective role of indole in NAFLD is in a myeloid cell PFKFB3-dependnet manner (Ma et al., 2020). Here, PFKFB3 is linked to metabolic dysfunction-associated steatotic liver disease.